A new method for testing urinary tract infections yields more information than what conventional methods can offer, according to new research from investigators at Weill Cornell Medicine, Cornell’s Meinig School of Biomedical Engineering and NewYork-Presbyterian.
In a study published June 20 in Nature Communications, researchers analyzed pieces of DNA, called cell-free DNA, isolated from the urine of kidney transplant patients. They discovered that this DNA provides valuable information about the bacterial and viral composition found within patients’ urine.
Clinicians often test for urinary tract infections with a urine culture that involves growing bacteria. “But some bacteria are harder to grow than others, and for conventional techniques you have to choose a specific set of tests to detect a specific bacterium,” said co-lead author Dr. John Richard Lee, an assistant professor of medicine at Weill Cornell Medicine and a nephrologist at NewYork-Presbyterian/Weill Cornell Medical Center. “This test, using urinary cell-free DNA, is less biased because it screens broadly for different kinds of infections, both common and rare.”
Urinary cell-free DNA (cfDNA) are floating molecules of DNA that are derived from the genomes of dying human or microbial cells. They are usually studied in blood plasma but are also present in the urine.
Investigators analyzed urine samples from 82 kidney transplant recipients receiving care at NewYork-Presbyterian/Weill Cornell Medical Center. By looking at the urinary cfDNA of these patients, the researchers not only identified the same microorganisms detected by conventional approaches but also other, less common microorganisms. They also were able to learn about the host response to infection and how fast bacteria were growing by carefully looking at the genome structures.
“With just one test, many pieces of information about bacteria and viruses, as well as antibiotic resistance, can be determined at the same time,” said co-lead author Dr. Iwijn De Vlaminck, an assistant professor of biomedical engineering at Cornell’s Ithaca campus.
The cfDNA fragments are short and fragmented, which makes it more difficult to analyze using DNA sequencing approaches. However, by optimizing cfDNA fragment analysis, only 1 ml of centrifuged urine was needed in this study.
The study was conducted by an interdisciplinary team that included: Philip Burnham, a graduate student in Dr. De Vlaminck’s biomedical engineering lab; Dr. Manikkam Suthanthiran, chief of the Division of Nephrology and Hypertension at Weill Cornell Medicine and NewYork-Presbyterian/Weill Cornell Medical Center; Dr. Darshana Dadhania, an associate professor of medicine at Weill Cornell Medicine and a nephrologist at NewYork-Presbyterian/Weill Cornell Medical Center; and Dr. Lars Westblade, an assistant professor of pathology and laboratory medicine and the associate director of the clinical microbiology laboratory at Weill Cornell Medicine.
Dr. Lee and Dr. De Vlaminck said that they hope to do a validation study to see if this test can be implemented into practice. This new test not only could be important for kidney transplant patients, who frequently contract viral and bacterial urinary tract infections, but also for the general population.